Skip to main content
SpringerLink
Log in

Comparative murine metabolism and disposition of class II anthracycline antibiotics

  • Original Articles
  • Anthracyclines, Metabolism
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

The metabolism and tissue distribution of aclacinomycin A (ACL), marcellomycin (MCM), and musettamycin (MST), three new anthracycline antibiotics, were compared after IV administration to mice. In plasma, total MCM- and ACL-derived fluorescence declined according to first-order kinetics, whereas an initial decline followed by a rebound was observed for MST. In plasma, MCM remained the predominant compound. ACL was eliminated more quickly, and was replaced by two metabolites, the reduced glycoside M1, and an aglycone. In the case of MST, two unidentified metabolites were observed in concentrations equivalent to that of the parent drug.

The three drugs were distributed widely to organs, but only ACL achieved measurable concentrations in the brain. Initially, high concentrations of all three drugs were present in the lungs, but these decreased quickly to values similar to those present in the liver and kidneys. Intermediate concentrations of the three drugs were measured in heart and skeletal muscle. Splenic concentrations of all three drugs rose progressively, reaching a maximum at 8 h after injection in the case of ACL and MST, and at 24 h after injection in the case of MCM. Concentrations of the metabolites of MCM and MST were low in all organs except liver and kidney, where the aglycones 7-deoxypyrromycinone and bisanhydropyrromycinone were seen. The metabolism of ACL was extensive. Aglycones were dominant in the liver and kidneys, whereas reduced glycosides predominated in the spleen. These observations indicate that the murine pharmacology of these three structurally similar drugs differs markedly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Andrews PA, Brenner DE, Chou FE, Kubo H, Bachur NR (1980) Facile and definitive determination of human Adriamycin and daunorubicin metabolites by high-pressure liquid chromatography. Drug Metab Dispos 8: 152

    Google Scholar 

  2. Benjamin RS, Riggs CE, Jr, Bachur NR (1977) Plasma pharmacokinetics of Adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 37: 1417

    Google Scholar 

  3. Casper ES, Gralla RS, Young CW (1981) Clinical phase I study of aclacinomycin A by an evaluation of an intermittent intravenous administration schedule. Cancer Res 41: 2417

    Google Scholar 

  4. Chang P, Tamburini JM, Dodion P, Riggs CE Jr, Bachur NR (1983) In vitro metabolism of marcellomycin. Proc Am Assoc Cancer Res 4: 258

    Google Scholar 

  5. Crooke ST, DuVernay VH, Galvan L, and Prestayko AW (1978) Structure-activity relationships of anthracyclines relative to effects on macromolecular syntheses. Mol Pharmacol 14: 290

    Google Scholar 

  6. Dodion P, Riggs CE Jr, Tamburini JM, Nicaise C, Wathieu M, Rozencweig M, Bachur NR (1983) Human pharmacokinetics of marcellomycin. Proc Am Soc Clin Oncol 2: 32

    Google Scholar 

  7. Dodion P, Egorin MJ, Tamburini JM, Riggs CE, Bachur NR (1984) The murine metabolism and disposition of marcellomycin. Drug Metab Dispos 12: 209

    Google Scholar 

  8. DuVernay VH, Mong S, Crooke ST (1980) Molecular pharmacology of anthracyclines: demonstration of multiple mechanistic classes of anthracyclines. In: Crooke ST, Reich SD (eds) Anthracyclines: current status and new developments. Academic, New York, pp 61–123

    Google Scholar 

  9. Egorin MJ, Clawson RE, Ross LA, Chou FE, Andrews PA, Bachur NR (1980) Disposition and metabolism of N,N-dimethyldaunorubicin and N,N-dimethyladriamycin in rabbits and mice. Drug Metab Dispos 8: 353

    Google Scholar 

  10. Egorin MJ, Clawson RE, Ross LA, Chou FE, Andres PA, Bachur NR (1981) Disposition and metabolism of adriamycin octanoyl hydrazone (NSC 233853) in mice and rabbits. Drug Metab Dispos 9: 240

    Google Scholar 

  11. Egorin MJ, Van Echo DA, Fox BM, Whitacre M, Bachur NR (1982) Plasma kinetics of aclacinomycin A and its major metabolites in man. Cancer Chemother Pharmacol 8: 41

    Google Scholar 

  12. Egorin MJ, Andres PA, Nakazawa H, Bachur NR (1983a) Purification and characterization of aclacinomycin A and its metabolites from human urine. Drug Metab Dispos 11: 167

    Google Scholar 

  13. Egorin MJ, Clawson RE, Ross LA, Friedman RD, Reich SD, Pollak A, Bachur NR (1983b) Murine metabolism and disposition of iron: adriamycin complexes. Cancer Res 43: 3253

    Google Scholar 

  14. Fourcade A, Farhi JJ, Bennoun M, Goldschmidt E, Tapiero H (1983) Fate of aclacinomycin-A and its metabolites. Effect on cell growth and macromolecular synthesis. Biochem Pharmacol 32: 1819

    Google Scholar 

  15. Joss RA, Kaplan S, Goldhirsch A, Varini M, Brunner KW, Cavalli F (1983) A phase I trial of marcellomycin with a weekly dose schedule. Eur J Cancer Clin Oncol 19: 455

    Google Scholar 

  16. Karanes C, Young JD, Samson MK, Smith LB, Franco LA, Baker LH (1983) Phase I trial of aclacinomycin A: A clinical and pharmacokinetic study. Invest New Drugs 1: 173–179

    Google Scholar 

  17. Knott GD (1979) MLAB: A mathematical modeling tool. Comput Programs Biomed 10: 271–280

    Google Scholar 

  18. Majima H (1980) Preliminary clinical study of aclacinomycin A. Recent Results Cancer Res 70: 75–81

    Google Scholar 

  19. Mathé G, de Jager R, Hulhoven R, Delgado M, Machover D, Ribaud P, de Vassal F, Gil-Delgado M, Misset JL, Gouveia J, Jasmin C, Hayat M, Gastiaburu J, Schwarzenberg L (1982) L'aclacinomycine-A dans les leucémies aigües et les lymphomes non-hodgkiniens leucémiques. Nouv Presse Med 11: 25–28

    Google Scholar 

  20. Muggia FM, Rozencweig M (1980) Goals for new anthracyclines at the National Cancer Institute. In: Crooke ST, Reich SD (edsz) Anthracyclines: current status and new developments. Academic, New York pp 1–9

    Google Scholar 

  21. Nettleton DE, Bradner WT, Bush JA, Coon AB, Moseley JE, Myllymaki RW, O'Herron RA, Schreiber RH, Vulcano AL (1977) New antitumor antibiotics: Musettamycin and marcellomycin from bohemic acid complex. J Antibiot (Tokyo) 30: 525–529

    Google Scholar 

  22. Nicaise C, Rozencweig M, De Marneffe M, Crespeigne N, Dodion P, Piccart M, Sculier JP, Lenaz L, Kenis Y (1983) Clinical phase I trial of marcellomycin with a single-dose schedule. Eur J Cancer Clin Oncol 19: 449–454

    Google Scholar 

  23. Oki T, Takeuchi T, Oka S, Umezawa H (1980) New anthracycline antibiotic aclacinomycin A: Experimental studies and correlations with clinical trials. Recent Results Cancer Res 76: 21–40

    Google Scholar 

  24. Reich SD, Bradner WT, Rose WC, Schurig JE, Madissoo H, Johnson DF, Du Vernay VH, Crooke ST (1980) Marcellomycin. In: Crooke ST, Reich SD (eds), Anthracyclines: current status and new developments. Academic, New York, pp 343–364

    Google Scholar 

  25. Van Echo DA, Whitacre M, Aisner J, Applefeld MM, Wirnik PH (1982) Phase I trial of aclacinomycin A. Cancer Treat Rep 66: 1127–1132

    Google Scholar 

  26. von Hoff DD, Rozencweig M, Piccart M (1982) The cardiotoxicity of anticancer drugs. Semin Oncol 9: 23–40

    Google Scholar 

  27. Wooley PV III, Ayoob MJ, Levenson SM, Smith FP (1982) A phase I clinical trial of aclacinomycin A administered on a five-consecutive day schedule. J Clin Pharmacol 22: 359–365

    Google Scholar 

  28. Young RC, Ozols RF, Myers CE (1981) The anthracycline antineoplastic drugs. N Engl J Med 305: 139–153

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Medicinal Chemistry and Pharmacology, Division of Cancer Treatment, National Cancer Institute, 20205, Bethesda, MD, USA

    Pierre Dodion & Nicholas R. Bachur

  2. Division of Developmental Therapeutics, University of Maryland Cancer Center, 22 South Greene Street, 21201, Baltimore, MD, USA

    Merrill J Egorin, Charles E. Riggs Jr, Thomas A Ferraro & Julie M. Tamburini

Authors
  1. Pierre Dodion
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Merrill J Egorin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charles E. Riggs Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas A Ferraro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Julie M. Tamburini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicholas R. Bachur
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

International Visiting Fellow at the National Institutes of Health (Bethesda, Md) and an International Fulbright Scholar (Washington, DC)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dodion, P., Egorin, M.J., Riggs, C.E. et al. Comparative murine metabolism and disposition of class II anthracycline antibiotics. Cancer Chemother. Pharmacol. 15, 153–160 (1985). https://doi.org/10.1007/BF00257527

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00257527

Keywords

Search

Navigation